Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines.
暂无分享,去创建一个
M. Pawlita | J. Sampson | A. Hildesheim | R. Herrero | A. Kreimer | T. Waterboer | P. Sehr | R. Sankaranarayanan | L. Pinto | T. Kemp | Sabrina H. Tsang | Martin Müller | P. Basu | G. Panicker | N. Bender | M. Sierra | John Schussler | E. Unger
[1] S. Chanock,et al. Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies , 2018, Vaccine.
[2] M. Pawlita,et al. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. , 2018, Vaccine.
[3] D. Lowy,et al. Explanations for the high potency of HPV prophylactic vaccines , 2018, Vaccine.
[4] J. Dillner,et al. Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development , 2018, Vaccine.
[5] M. Gail,et al. Design and statistical considerations for studies evaluating the efficacy of a single dose of the human papillomavirus (HPV) vaccine. , 2018, Contemporary clinical trials.
[6] M. Gail,et al. Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial , 2018, Journal of the National Cancer Institute.
[7] D. Harper,et al. HPV vaccines - A review of the first decade. , 2017, Gynecologic oncology.
[8] D. Lowy,et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. , 2015, The Lancet. Oncology.
[9] D. Lowy,et al. Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. , 2015, The Lancet. Oncology.
[10] M. Einstein,et al. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial , 2014, Human vaccines & immunotherapeutics.
[11] M. Pawlita,et al. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18. , 2014, Vaccine.
[12] S. Wacholder,et al. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. , 2014, Vaccine.
[13] D. Lowy,et al. Comparison of Antibody Responses to Human Papillomavirus Vaccination as Measured by Three Assays , 2014, Front. Oncol..
[14] D. Lowy,et al. Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial , 2013, Cancer Prevention Research.
[15] J. Singer,et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. , 2013, JAMA.
[16] L. Bruni,et al. Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries. A WHO/ICO HPV Information Centre Report. , 2012, Vaccine.
[17] M. Jit,et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. , 2012, The Lancet. Infectious diseases.
[18] Who,et al. Human papillomavirus vaccines: WHO position paper. , 2009, Biologicals : journal of the International Association of Biological Standardization.